Blood cell transplantation (BCT) is now common practice in the autologous setting. We performed a pilot study of allogeneic BCT, collected after the priming of an HLA-identical sibling with a glycosylated rhu-G-CSF (lenograstim) (10 g/kg). genitors allows easy harvest with cytapheresis, and collection of a better quality graft than after traditional BM harvest.
genitors allows easy harvest with cytapheresis, and collection of a better quality graft than after traditional BM harvest. 2 In the autologous setting, this effectively leads to faster neutropenic reconstitution but also to accelerated platelet reconstitution. This quicker hematopoietic recovery resulted in decreased transplant-related morbidity, shorter duration of hospitalization and reduced transfusion requirement. 3, 4 Associated with a reduction in procedural cost this motivated physicians to consider autologous transplantation for a larger number of patients. The shift from BM to blood cell (BC) transplantation occurred within a few years and coincided with a rapid increase in the number of autologous transplants world-wide. 5 The rapid development of autologous BC transplantation (BCT) provided the necessary experience and led to modification of the procedure for the allogeneic setting. In this situation, early interest arose for the same reasons as in the autologous situation: harvesting cells easily and without general anesthesia from normal donors, infusing more progenitors and so potentially decreasing morbidity and costs. The main expectation, in this setting, remains that the change in technology will induce a substantial decrease in transplant-related toxicity. However specific restrictions arise from simply adopting the procedure: first, the easier collection procedure has to be balanced with the need for using G-CSF as a mobilizing agent in normal donors, with regard to its potential longterm deleterious effects in normal individuals; 6 second, the reinfusion of a large number of immuno-competent cells may be of interest in provoking a more potent antitumoral effect, but may also increase the risk of graft-versus-host disease (GVHD).
Preliminary reports have assessed short-term feasibility and have, in part, already supplied some answers. [7] [8] [9] However, more data are necessary especially with a longer follow-up prior to this procedure being definitively accepted. Here, we report the 3-year follow-up of an allogeneic BC transplantation trial in which 54 patients treated for hematological malignancies were included at six different centers. Besides the number of patients, the multi-center aspect of the trial and the length of follow-up, this also represents the first report using a glycosylated form of rhu-G-CSF (lenograstim) as a mobilising agent in the allogeneic setting.
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Patients and methods
Patients
From February 1995 until June 1996, 54 patients treated for leukemia (chronic myeloid leukemia (CML): n = 17; acute myeloid leukemia (AML): n = 14; acute lymphoblastic leukemia (ALL): n = 15); or myelodysplastic syndrome (MDS) (n = 8) were treated at six different transplant centers in France (Table 1) . Four had received a previous transplant (auto: 3; allo: 1). These 54 patients are among a subset of 62 consecutive patients entered in the same pilot study investigating the use of lenograstim (Laboratoire Rhône-Poulenc Rorer, Montrouge, France) for mobilization of hematopoietic progenitors and their use in transplants in the allogeneic setting. Eight patients were excluded in order to have a more uniform population for analysis (severe aplastic anemia (n = 2), multiple myeloma (n = 1), nonHodgkin's lymphoma (n = 4) and Hodgkin's disease (n = 1)). Their outcome is similar to the patients presented. According to disease status at time of transplant, patients were classified as those who were transplanted early in the course of their disease (early transplant: n = 37), or after failure of initial therapy (second intention transplant: n = 17) ( Table 1 ). In order to evaluate the procedure in a population reflecting the most usual indications in France (ie transplant as first-line and at age under 45 years), a population used notably in all the previous national prospective trials, [11] [12] [13] an analysis was also performed on patients transplanted early and aged 45 or less (n = 28). This cohort was arbitrarily named 'standard population'. We previously reported the early outcome and chimerism study of 10 patients included in this study.
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Methods
Conditioning regimens
Depending on disease status and center programs, various myelo-ablative treatments were used. The majority (n = 35: 65%) were prepared with cytoxan (120 mg/kg) and total body irradiation (TBI) 15 (median dose 12 Gy (11-13.5 Gy) with a median of six fractions (5-6) over a median time of 3 days (3-5); in addition 10 patients received a second drug: VP16 (60 mg/kg) (n = 6), or melphalan (140 mg/m 2 ) (n = 4). Two patients were prepared with TBI, aracytine and melphalan. 16 The seven remaining patients were not treated with TBI, but rather received busulfan (16 mg/kg) and cytoxan (200 mg/kg) (n = 5) 17 or melphalan (140 mg/m 2 (n = 2)).
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Graft collection and reinfusion
Day of cell infusion is designated as day 0. Mobilization consisted of daily administration of lenograstim, glycosylated rhu-G-CSF (Laboratory Rhône-Poulenc Rorer) at a dose of 10 g/kg. Treatment started on day −5 and ended on day −1. The first cytapheresis was performed on day −1, kept overnight at 4°C and reinfused on day 0 with the second one. Per protocol, a minimum of two cytaphereses were scheduled and the collection of at least 6 × 10 6 CD34/kg was the aim. If this goal was not reached with two cytaphereses, a third one was performed and infused on day 1 after one more s.c. administration of lenograstim to the donor on day 0.
GVHD prophylaxis
Patients received post-graft immunosuppression consisting of 'short' methotrexate (MTX) (days 1, 3 and 6) (n = 37) or prednisone (PDN) (n = 17) and cyclosporin A (CsA) according to institutional protocols. 19 
Immunophenotyping
The graft was analyzed in terms of hematopoietic progenitors (CD34 + cells) and lymphoid sub-populations (CD3 + , CD4
+ , CD8 + , CD19 + and CD56 + cells) using standard procedures at each center.
Statistics
Patients who died post-transplant after relapse were considered as dying of relapse irrespective of the actual cause. Transplant mortality was defined as death without relapse. GVHD (acute or chronic) was listed as the cause of death when patients died during the course of grade 3-4 aGVHD or extensive chronic GVHD. Disease-free survival was defined as the occurrence of relapse or death, whichever occurred first. Kaplan-Meier product-limit estimates were used to estimate the probability of neutrophil (time to reach the first of 3 days with 0.5 × 10 9 neutrophils/l) and platelet recovery (time to reach the first of 3 days with 25 × 10 9 and 50 × 10 9 platelets/l without platelet transfusion during a 5-day period), acute GVHD, transplant mortality, relapse, survival and DFS. 20 Comparison of two such probabilities relied on the Mantel-Haenszel test. 21 All procedures were performed after obtaining written informed consent from recipient and donor. The protocol was approved by the Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale (CCPPRB) of Marseille 2.
Results
Patient and donor characteristics are shown in Table 1 .
Fifty-four donors received a total of 273 subcutaneous administrations of lenograstim. Thirty adverse events were reported in 19 (35%) donors, but none of them were considered as serious enough to discontinue treatment. Seventeen (57%) were related to bone pain or myalgia: these effects were easily treated and resolved after discontinuation of lenograstim. Other events were fatigue (n = 6), skin rashes (n = 4), nausea (n = 1), conjunctivitis (n = 1) and chills (n = 1). No particular clinical event was reported during cytapheresis. All donors experienced a big increase in neutrophil count (from 3.9 (2-8.9) at steady state to 36 × 10 9 /l (13-64) on day −1 after four lenograstim administrations) (Figure 1 ). Conversely, they experienced a drop in platelet count after cytapheresis with a median decrease of 54% (11-87%). For 22 (41%), counts dropped to under 100 × 10 9 /l: for these 22 donors, the median lowest number reached was 68 × 10 9 /l (24-99) and in five cases, counts were under 50 × 10 9 /l. Thrombopenia occurred at a median of day 0 (−1−+1). In all situations, this decrease was transient, bleeding did not occur and platelet transfusion was not necessary. During the course of the study it was decided to set up an annual medical follow-up of the donor. Because this was decided late, only donors whose sibling was still alive have been contacted: of the 26 donors concerned, 12 (47%) accepted a physical examination and a blood test at a median of 22 (3-23) months post-transplant. No complaints or physical or biological abnormalities were recorded. All donors accepted carrying out such a follow-up every year for a 5-year period. A median of two cytaphereses (one cytapheresis: 4 (7%); two cytaphereses: 43 (80%); three cytaphereses: 7 (13%)) was performed. The composition of the infused graft is shown in Figure 2 and represents a high increase in all the studied sub-populations in comparison with the usual BM harvest. 11 × 10 6 (3.5-29.1) CD34 + cells/kg were infused to patients. The pre-established minimum number of 6 × 10 6
CD34
+ /kg, was reached on 46 occasions (85%). This was after the first cytapheresis in 29 cases (54%), after the second in 15 patients (28%), and after the third in two patients. Eight patients received less than 6 × 10 6 CD34 + /kg and were infused with a median of 4.6 (3.5-5.9) × 10 6
+ /kg collected in a median of three (2-3) Table 2 . Fifty-one patients recovered from neutropenia. Two patients died on day 10 and 14 before reaching 0.5 × 10 9 neutrophils/l. Two patients experienced early graft failure (primary (n = 1) or secondary rejection (n = 1) despite the reinfusion of more than 10 × 10 6 CD34 + /kg. Chimerism studies did not contribute to either of the two cases. Both patients received additional immunosuppression and reinfusion of a second BC graft. Both engrafted promptly, but experienced severe GVHD which was lethal in one case. Eleven (21%) patients died before reaching 25 × 10 9 platelets/l and 18 (35%) before 50 × 10 9 platelets/l. The median time to reach 0.5 × 10 9 neutrophils or 25 × 10 9 platelets was not directly related to the number of CD34 + cells infused. However, there was a trend towards more patients recovering at these end-points on days 14 and 21, respectively, when higher numbers of CD34 + cells were infused ( Figure 3 ). These data suggest that 10 × 10 6 may represent a threshold dose of CD34 + cells necessary for optimal hematopoietic reconstitution. Difference in time of recovery was not significant between patients treated with MTX and those treated with PDN, although there was a tendency towards a shorter recovery (by 2 to 3 days) for the latter (data not shown).
Overall probabilities of developing GVHD are shown in Table 2 . The number of infused CD3
+ cells was not predictive for the incidence or the severity of any form of GVHD.
Relapse occurred in six patients at a median time of 160 (75-505) days (Figures 4 and 5 ): all ultimately died 34 (12-348) days later. 
Discussion
This report is the first to describe the use of lenograstim as a mobilizing agent for hematopoietic progenitors in normal HLA-identical sibling donors, in order to perform allogeneic transplantation. We established that it is well tolerated and that it is efficacious in mobilizing progenitor cells. One third of donors experienced minor side-effects attributable to lenograstim. These events did not differ from sideeffects previously reported during mobilization with other G-CSF. Cytapheresis systematically induced a drop in platelet counts as already reported by others. 22 While never a problem in this study, it may, however, be anticipated that the reinfusion of autologous platelets soon after apheresis may minimise this drop and improve safety of the procedure, especially when more than two cytaphereses are required. 23 Collection of hematopoietic progenitors was satisfactory. The lowest number of CD34 + cells collected was 3.5 × 10 6 /kg which seems high enough to permit engraftment. [7] [8] [9] 24, 25 Eighty-five percent of patients reached the target value of 6 × 10 6 CD34 + cells/kg. This occurred with one cytapheresis in 54%. Two graft failures were noted. This has not been previously reported and needs to be looked at in larger populations. If confirmed, this 4% probability of graft failure in HLA geno-identical allogeneic transplants will be of concern and will question the validity of CD34
+ enumeration in such situations. Despite these two failures it seems that, as already reported by several authors, the use of BC in the allogeneic setting is associated with prompt neutrophil and platelet recovery. 25 We previously established that full chimerism as early as day 15 occurs in both myeloid and lymphoid sub-populations. 14 Compared to the BMT setting, this recovery may not be accelerated to the same degree as after autologous BC transplantation. The use of MTX after transplant, as well as the occurrence of aGVHD, may limit this benefit. The optimal number of CD34 + cells to be reinfused is presently unknown. High numbers of infused cells may, however, favor rapid hematopoietic recovery (Figure 3 ). Our data may even suggest a threshold dose for CD34
+ cells as has already been reported after autologous BCT. 26 The amount of CD34
+ cells infused may also favor very long-term engraftment. 27 Larger cohorts and longer follow-up are probably necessary to answer this question.
As already reported, a very high number of CD3 + cells was reinfused to patients. 24, 25 However, the incidence of moderate to severe aGVHD was 56 Ϯ 6% which did not represent a major increase, in comparison to allogeneic BMT particularly considering that more than 25% of patients were older than 45 years of age. Seventy-one per cent of the patients alive on day 100 had signs of aGVHD. cGVHD was extensive in two of three of the cases and appeared de novo in 44%. In our experience, these numbers seem higher than usual after BMT but only comparative studies will clarify the relationship between graft characteristics and GVHD. As already emphasised by others, 28 more investigation is required into this subject to answer questions such as the relative importance of numbers of different sub-populations of immunocompetent cells or their function after priming 29, 30 and the relationship between these elements and occurrence and severity of acute or chronic GVHD, which is presently unknown. Prospective clinical and biological evaluation is presently ongoing and should hopefully answer some of these questions.
One reason for shifting to alloBCT was the hypothesis that this would decrease the initial transplant-related morbidity and mortality. This analysis does not support this hypothesis, especially for older patients or those with advanced disease. In the cohort defined as 'standard population', transplant mortality is 18% (8-36) with two of the six toxic deaths occurring prior to day 100. Again, these results do not greatly differ from those of BMT in the same population. The main reason for the lack of decrease in transplant-related mortality is obviously the fact that GVH incidence and severity were not significantly changed. Similarly, any GVL effect does not seem to be modified at least in the short term. Three patients in the standard population relapsed, which is comparable with BMT results. Of the 17 patients with a higher risk of relapse, 12 died of transplant-related toxicities, seven during the first 100 days, which precludes any conclusions about a GVL effect. Finally, a large number of immunocompetent cells were reinfused but this did not influence the incidence of acute GVHD, or an anti-leukemic effect in patients with advanced disease. The impact of G-CSF on the function of such cells has already been discussed. 29 In conclusion, this report, besides the specific information on lenograstim, confirms previous analyses of the feasibility of BC transplants, with a larger population and longer follow-up. [7] [8] [9] 28 It also provides data on a homogeneous cohort of good-risk patients. In addition, although not controlled with a BMT cohort, this study suggests an increased incidence of chronic GVHD and especially of de novo chronic GVHD. Our observations stress the need for more detailed and cautious evaluation of these practices, before their widespread use. Graft failures and chronic GVHD occur. Furthermore, incidence of other more specific complications may very well be underestimated, as for instance, the risk of fatal hemolysis in so called 'minor ABO incompatibility' situations that we have previously reported. 31 For these reasons, it seems that patients should not be treated with this technology outside clinical trials and efforts should be made to participate in prospective evaluations. The preliminary results of the first randomized study have just been reported. 32 In addition, economic aspects are critical: the cost of this change must be clearly determined. If it seems that early cost is lower than in BMT, 33 as already documented in the autologous setting, 4 evaluation is needed with a longer follow-up. This is presently being undertaken in a prospective trial from the Société Française de Greffe de Moelle where clinical evaluation is carried out in combination with economic and quality of life assessments. Finally, the major cause of mortality remains GVHD. This indicates the need to assess new forms of immunomodulation and to better determine predictive values of parameters used to evaluate the graft composition. 23, 34 
